ASP Isotopes

ASP Isotopes Equity Ratio

The Equity Ratio of ASP Isotopes (ASPI) as of Nov 18, 2026 is 40.99 %. In the previous year, Equity Ratio was 50.77 % — a change of -19.26% (lower).

Equity Ratio

40.99 %

YoY

-19.26%

Last updated:

Equity Ratio of ASP Isotopes is 2025 40.99 % . Equity Ratio of ASP Isotopes was 2024 50.77 % . It decreases by -19.26% lower compared to the previous year.

The ASP Isotopes Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2021
83.97 USD
Jan 1, 2022
78.56 USD
Jan 1, 2023
53.98 USD
Jan 1, 2024
50.77 USD
Jan 1, 2025
40.99 USD
The ASP Isotopes Equity Ratio history
YEAREquity RatioYoY
40.99 %-19.26%
50.77 %-5.96%
53.98 %-31.29%
78.56 %-6.44%
83.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ASP Isotopes Stock analysis

What does ASP Isotopes do? ASP Isotopes, Inc. generates revenue through the development and commercialization of enriched isotopes using its Aerodynamic Separation Process (ASP technology). The company focuses on producing Carbon-14 (C-14), Molybdenum-100 (Mo-100), and Silicon-28 (Si-28) for specialized markets, with plans to expand into Uranium-235 (U-235) for the nuclear energy sector. Its subsidiaries, ASP Isotopes Guernsey Limited and Enriched Energy LLC, handle high-value isotope production and uranium development, respectively. The company licenses ASP technology from Klydon Proprietary Ltd for all isotope-related activities. The target customers for C-14, Mo-100, and Si-28 are highly specialized end markets requiring low-volume, high-value isotopes. Enriched Energy LLC specifically targets the nuclear energy market with uranium products. ASP Isotopes Guernsey Limited focuses on niche applications where isotope enrichment is critical, such as medical and industrial uses. The company’s revenue model relies on the sale of these enriched isotope products to specialized industries rather than mass-market consumers. ASP Isotopes, Inc. operates under a pre-commercial stage, meaning it is still developing its production capabilities and has not yet achieved full-scale commercialization. The company’s initial revenue streams will come from the sale of C-14, Mo-100, and Si-28, with future expansion into U-235 expected to diversify its product portfolio. The Aerodynamic Separation Process (ASP technology) is central to its business model, enabling the enrichment of natural isotopes into higher concentration products for specialized applications. ASP Isotopes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ASP Isotopes stock

Equity Ratio of ASP Isotopes is 40.99 % in 2025.

Equity Ratio of ASP Isotopes changed from 50.77 % to 40.99 %, representing a -19.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio ASP Isotopes since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's ASP Isotopes with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ASP Isotopes

All Key Metrics — ASP Isotopes